Institutional compliance & research boundaries

Clinical perspectives on unregulated peptide administration.

Academic medical literature and clinical toxicology advisories have established definitive positions regarding the human administration of non-approved synthetic peptides obtained through online channels. Lyotide Scientific endorses these clinical warnings without reservation and aligns its distribution framework accordingly.

Medical advisory

Harvard Health Publishing

“As a clinician, I do not recommend injecting yourself with peptides.”

Dr Pieter Cohen, Associate Professor of Medicine, Harvard Medical School

“When you’re talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else.”

Dr Pieter Cohen, quoted in Harvard Health Publishing

Academic literature highlights the widespread online commercialization of unapproved investigational compounds under the pro forma designation of “research chemical” or “research use only,” frequently sold directly to end consumers. Lyotide Scientific repudiates this consumer-facing gray-market posture.

Operational boundaries
Qualified enterprise sphereProhibited consumer sphere
Verified commercial R&D accountsRetail consumers / general public
In vitro laboratory protocolsIn vivo human or veterinary use
Certified laboratory facilitiesResidential / private delivery
Neutral, unlabeled primary unitsFinished consumer-packaged goods
Where we stand

Commercial boundaries and governance

We do not seek to qualify or distinguish our inventory from academic clinical warnings through promotional claims. Our portfolio comprises non-approved chemical reagents that have not undergone the safety, efficacy, and toxicology evaluations required for human clinical approval by the United States Food and Drug Administration (FDA) or foreign equivalents.

Client demographics
Materials are restricted to commercial enterprises, biotechnology organizations, universities, and accredited research facilities. We do not fulfill orders to consumers, patients, or dispensing medical practices.
Unit packaging
Shipped in unprinted ten-vial institutional boxes accompanied by analytical synthesis paperwork. Products contain no dosing guidelines or therapeutic guidance.
No therapeutic indications
Lyotide Scientific makes no claims—expressed or implied—regarding the physiological efficacy, bioactivity, or clinical utility of any distributed substance.
Individual consumers
Individuals seeking peptides for therapeutic, cosmetic, or performance applications are strictly ineligible to hold an account with Lyotide Scientific and are urged to consult a board-certified physician.

Related reading: analytical scope and contaminant profiles and compounding regulatory landscape.

Taylor, M. (Reviewed by Cohen, P., MD). (2026, July 7). Peptides: What they are, potential benefits, and safety concerns. Harvard Health Publishing. Read the original article. Quotations are Harvard Health’s; the commentary is ours. Harvard Health and Dr Pieter Cohen do not endorse, sponsor, or maintain affiliation with Lyotide Scientific.